Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - Cerevel Therapeutics Holdings, Inc. | brhc10016853_ex32-1.htm |
| EX-31.2 - EXHIBIT 31.2 - Cerevel Therapeutics Holdings, Inc. | brhc10016853_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - Cerevel Therapeutics Holdings, Inc. | brhc10016853_ex31-1.htm |
| EX-10.23 - EXHIBIT 10.23 - Cerevel Therapeutics Holdings, Inc. | brhc10016853_ex10-23.htm |
| EX-10.22 - EXHIBIT 10.22 - Cerevel Therapeutics Holdings, Inc. | brhc10016853_ex10-22.htm |
| EX-10.21 - EXHIBIT 10.21 - Cerevel Therapeutics Holdings, Inc. | brhc10016853_ex10-21.htm |
| EX-10.20 - EXHIBIT 10.20 - Cerevel Therapeutics Holdings, Inc. | brhc10016853_ex10-20.htm |
| EX-10.19 - EXHIBIT 10.19 - Cerevel Therapeutics Holdings, Inc. | brhc10016853_ex10-19.htm |
| EX-10.18 - EXHIBIT 10.18 - Cerevel Therapeutics Holdings, Inc. | brhc10016853_ex10-18.htm |
| 10-Q - 10-Q - Cerevel Therapeutics Holdings, Inc. | brhc10016853_10q.htm |
EXHIBIT 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Cerevel Therapeutics Holdings, Inc. (the “Company”) for the period ended September 30, 2020,
as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Kathy Yi, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that, to her knowledge:
| (3) |
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
| (4) |
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
|
Date: November 16, 2020
|
By:
|
/s/ Kathy Yi
|
|
Kathy Yi
|
||
|
Chief Financial Officer
|
||
|
(Principal Financial Officer)
|